Physicians' Academy for Cardiovascular Education

Managing Diabetes & CVD: Exploring new evidence and opportunities

June 12, 2015

EBAC Accredited symposium held on August 30, 2015 during ESC 2015, London, UK


Videorecordings and teaching slides


Diabetes & Cardiovascular Disease:
The risk factor to be challenged

Prof. John E Deanfield,
University College London




What is the story about Diabetes & CVD:
Rationale for a multifactorial approach

Prof. D John Betteridge,
University College London


 

SGLT2 inhibition in the management of type 2 diabetes:
Potential impact on CVD Risk

Prof. Silvio E Inzucchi,
New Haven, CT, USA




SGLT2 inhibitor outcome trials:
Future opportunities

Dr David Fitchett,
Toronto, Canada




Educational objectives

  • Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
  • Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
  • Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, and related markers and potential cardiovascular outcomes

Educational programme & downloadable teaching slides

Co-Chairmen:
John E Deanfield, MD - University College London, London, United Kingdom
D John Betteridge, MD - University College London London, United Kingdom
 

Diabetes & Cardiovascular Disease: The risk factor to be challenged

Teaching slides prepared and presented by Prof. John E Deanfield, London at EBAC accredited symposium ' Managing Diabetes & CVD: Exploring new evidence and opportunities'
 

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

Teaching slides prepared and presented by Prof. D John Betteridge, London at EBAC accredited symposium ' Managing Diabetes & CVD: Exploring new evidence and opportunities'
 

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Teaching slides prepared and presented by Prof. Silvio E Inzucchi, New Haven, CT, USA at EBAC accredited symposium ' Managing Diabetes & CVD: Exploring new evidence and opportunities'
 

SGLT2 inhibitor outcome trials: Future opportunities

Teaching slides prepared and presented by Dr David Fitchett, Toronto, Canada at EBAC accredited symposium ' Managing Diabetes & CVD: Exploring new evidence and opportunities'
 

Financial support

Supported by unrestricted educational grants from Boehringer Ingelheim - Lilly